Can biomarkers guide MS treatment? new trial aims to find out

NCT ID NCT03109288

First seen Jun 26, 2026 · Last updated Jul 29, 2026 · Updated 7 times

Summary

This study tests whether changes in spinal fluid biomarkers can predict which drug or drug combination works best for people with progressive multiple sclerosis (MS). Participants will take one or two of five drugs (cilostazol, leucovorin, pirfenidone, dantrolene, or pioglitazone) for up to 18 months. The goal is to slow disability progression by tailoring treatment to each person's unique disease activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Cilostazol, Leucovorin, Pirfenidone, Dantrolene, Pioglitazone
What this could lead to
If successful, this could lead to personalized combination therapies for progressive MS, slowing disability progression based on individual biomarkers.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 250 participants, so results may not apply to all MS patients. The drugs may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.